Daniel Joseph OConnell - Jan 19, 2024 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role: President and CEO, Director
Signature: /s/ Derek Meisner, Attorney-in-Fact
Stock symbol: ABOS
Transactions as of: Jan 19, 2024
Transactions value $: -$52,753
Form type: 4
Date filed: 1/19/2024, 07:07 PM
Previous filing: Jan 4, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABOS	Common Stock	Sale	-$52.8K	-15.2K	-2.94%	$3.47	502K	Jan 19, 2024	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	Represents the number of shares sold by the Reporting Person in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2023.
F2	The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $3.3950 to $3.6500. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

Represents the number of shares sold by the Reporting Person in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2023.

The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $3.3950 to $3.6500. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.